Arrowhead Pharmaceuticals Inc. (ARWR) reached a new 52-week high of $31.13, capping off a strong upward trend that has seen the stock gain over 85% in the past six months and more than 55% year-to-date. The surge reflects growing confidence in the company's RNA interference or RNAi platform, late-stage pipeline progress, and its lead candidate, plozasiran, which is currently under FDA review with a PDUFA action date set for November 18, 2025.
The stock closed Friday's regular session at $29.72, with intraday trading ranging between $29.51 and $31.13, supported by a volume of over 3 million shares, well above its average of 2.32 million shares. Arrowhead now commands a market capitalization of about $4.11 billion.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.